NASDAQ:BDSX - Biodesix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.33
  • Forecasted Upside: 61.36 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$15.70
▲ +0.05 (0.32%)

This chart shows the closing price for BDSX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biodesix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDSX

Analyst Price Target is $25.33
▲ +61.36% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Biodesix in the last 3 months. The average price target is $25.33, with a high forecast of $31.00 and a low forecast of $22.00. The average price target represents a 61.36% upside from the last price of $15.70.

This chart shows the closing price for BDSX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Biodesix.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021Morgan StanleyLower Price TargetOverweight$25.00 ➝ $23.00High
3/18/2021Morgan StanleyBoost Price TargetOverweight$20.00 ➝ $25.00High
2/2/2021Canaccord GenuityBoost Price TargetBuy$27.00 ➝ $31.00Low
1/11/2021Canaccord GenuityBoost Price TargetBuy$26.00 ➝ $27.00High
11/23/2020Canaccord GenuityInitiated CoverageBuy$26.00Low
11/23/2020William BlairInitiated CoverageOutperformLow
11/23/2020Morgan StanleyInitiated CoverageOverweight$20.00Low
11/23/2020BTIG ResearchInitiated CoverageBuy$22.00Low
(Data available from 6/21/2016 forward)
Biodesix logo
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $15.70
Low: $15.27
High: $16.05

50 Day Range

MA: $15.42
Low: $12.14
High: $19.37

52 Week Range

Now: $15.70
Low: $10.85
High: $31.99

Volume

7,619 shs

Average Volume

97,409 shs

Market Capitalization

$421.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biodesix?

The following Wall Street analysts have issued stock ratings on Biodesix in the last twelve months: BTIG Research, Canaccord Genuity, Morgan Stanley, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BDSX.

What is the current price target for Biodesix?

3 Wall Street analysts have set twelve-month price targets for Biodesix in the last year. Their average twelve-month price target is $25.33, suggesting a possible upside of 61.4%. Canaccord Genuity has the highest price target set, predicting BDSX will reach $31.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $22.00 for Biodesix in the next year.
View the latest price targets for BDSX.

What is the current consensus analyst rating for Biodesix?

Biodesix currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BDSX will outperform the market and that investors should add to their positions of Biodesix.
View the latest ratings for BDSX.

What other companies compete with Biodesix?

How do I contact Biodesix's investor relations team?

The company's listed phone number is 303-417-0500. The official website for Biodesix is www.biodesix.com.